Current understandings of Helicobacter pylori, peptic ulcer and gastroesophageal reflux disease

Minerva Gastroenterologica e Dietologica

Volumn 52, Issue 3, 2006, Pages 235-248

  Liu, Y ^a   Akiyama, J ^a   Graham, D Y ^b,c  

^a NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Gastroesophageal reflux disease; Helicobacter pylori; Peptic ulcer, diagnosis; Peptic ulcer, therapy

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; PROTON PUMP INHIBITOR; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

BARRETT ESOPHAGUS; DISEASE ASSOCIATION; ERADICATION THERAPY; GASTRITIS; GASTROESOPHAGEAL REFLUX; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; LOWER ESOPHAGUS SPHINCTER; PATIENT CARE; PEPTIC ULCER; REVIEW; STOMACH SECRETION;

GASTROESOPHAGEAL REFLUX; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; PEPTIC ULCER;

EID: 33750614934     PISSN: 00264776     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (99)

1. Steer HW. Ultrastructure of cell migration through the gastric epithelium and its relationship to bacteria. J Clin Pathol 1975;28:639-46.
2. Steer HW, Colin-Jones DG. Mucosal changes in gastric ulceration and their response to carbenoxolone sodium. Gut 1975;16:590-7.
3. Steer HW. The gastro-duodenal epithelium in peptic ulceration. J Pathol 1985;146:355-62.
4. Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet 1983;1:1273-5.
5. Marshall BJ, Royce H, Annear DI, Goodwin CS, Pearman JW, Warren JR et al. Original isolation of Campylobacter pyloridis from human gastric mucosa. Microbios Lett 1984;25:83-8.
6. Marshall BJ, Armstrong JA, McGechie DB, Glancy RJ. Attempt to fulfil Koch's postulates for pyloric Campylobacter. Med J Aust 1985;142:436-9.
7. Parsonnet J, Hansen S, Rodriguez L, Gelb AB, Warnke RA, Jellum E et al. Helicobacter pylori infection and gastric lymphoma. N Engl J Med 1994;330:1267-71.
8. Benedict EB, Sweet RH. Benign stricture of the esophagus. Gastroenterology 1948;11:618-28.
9. Lanza FL, Graham DY. Bougienage is effective therapy for most benign esophageal strictures. JAMA 1978;240:844-7.
10. Graham DY, Smith JL, Patterson DJ. Why do apparently healthy people use antacid tablets? Am J Gastroenterol 1983;78:257-60.
11. Boyd EJ. The prevalence of esophagitis in patients with duodenal ulcer or ulcer-like dyspepsia. Am J Gastroenterol 1996;91:1539-43.
12. Moraes-Filho JP, Zaterka S, Pinotti HW, Bettarello A. Esophagitis and duodenal ulcer. Digestion 1974;11:338-46.
13. Moraes-Filho JP. Lack of specificity of the acid perfusion test in duodenal ulcer patients. Am J Dig Dis 1974;19:785-90.
14. Flook D, Stoddard CJ. Gastro-oesophageal reflux and oesophagitis before and after vagotomy for duodenal ulcer. Br J Surg 1985;72:804-7.
15. Earlam RJ, Amerigo J, Kakavoulis T, Pollock DJ. Histological appearances of oesophagus, antrum and duodenum and their correlation with symptoms in patients with a duodenal ulcer. Gut 1985;26:95-100.
16. Goldman MS Jr, Rasch JR, Wiltsie DS, Finkel M. The incidence of esophagitis in peptic ulcer disease. Am J Dig Dis 1967;12:994-9.
17. Behar J, Biancani P, Sheahan DG. Evaluation of esophageal tests in the diagnosis of reflux esophagitis. Gastroenterology 1976;71:9-15.
18. Winkelstein A. Peptic esophagitis with duodenal ulcer. Am J Surg 1957;93:234-7.
19. Casula G, Jordan PH Jr. Is an antireflux procedure necessary in conjunction with parietal cell vagotomy in the absence of preoperative reflux? Am J Surg 1987;153:215-20.
20. Csendes A, Oster M, Moller JT, Flynn J, Funch-Jensen P, Overgaard H et al. Gastroesophageal reflux in duodenal ulcer patients before and after vagotomy. Ann Surg 1978;188:804-8.
21. Cruze K, Byron FX, Hill JT. The association of peptic ulcers and asymptomatic hiatal hernia. Surgery 1959;46:664-8.
22. Winkelstein A, Wolf BS, Som ML, Marshak RH. Peptic esophagitis with duodenal or gastric ulcer. JAMA 1954;154:885-9.
23. Wallin L. Acid gastro-oesophageal reflux pattern in duodenal ulcer patients related to dyspeptic symptoms. Scand J Gastroenterol 1980;15:151-5.
24. Wallin L. The influence of cimetidine on the acid gastro-oesophageal reflux in duodenal ulcer patients. Scand J Gastroenterol 1980;15:157-63.
25. Graham DY. Helicobacter pylori is not and never was " protective" against anything, including GERD. Dig Dis Sci 2003;48:629-30.
26. Graham DY. The changing epidemiology of GERD: geography and Helicobacter pylori. Am J Gastroenterol 2003;98:1462-70.
27. Graham DY. Helicobacter pylori and perturbations in acid secretion: the end of the beginning. Gastroenterology 1996;110:1647-50.
28. Graham DY, Dixon MF. Acid secretion, Helicobacter pylori, and peptic ulcer disease. In: Graham DY, Genta RM, Dixon MF, editors. Gastritis. Philadelphia: Lippincott Williams & Wilkins; 1999.p.177-88.
29. McColl KE, el-Omar E, Gillen D. Interactions between H. pylori infection, gastric acid secretion and anti-secretory therapy. Br Med Bull 1998;54:121-38.
30. Liu Y, Vosmaer GD, Tytgat GN, Xiao SD, Ten Kate FJ. Gastrin (G) cells and somatostatin (D) cells in patients with dyspeptic symptoms: Helicobacter pylori associated and non-associated gastritis. J Clin Pathol 2005;58:927-31.
31. Labenz J, Blum AL, Bayerdorffer E, Meining A, Stolte M, Borsch G. Curing Helicobacter pylori infection in patients with duodenal ulcer may provoke reflux esophagitis. Gastroenterology 1997;112:1442-7.
32. Bercik P, Verdu EF, Armstrong D, Idstrom JP, Cederberg C, Marken M et al. The effect of ammonia on omeprazole-induced reduction of gastric acidity in subjects with Helicobacter pylori infection. Am J Gastroenterol 2000;95:947-55.
33. Verdu EF, Fraser R, Armstrong D, Blum AL. Effects of omeprazole and lansoprazole on 24-hour intragastric pH in Helicobacter pylori-positive volunteers. Scand J Gastroenterol 1994;29:1065-9.
34. Verdu EF, Armstrong D, Idstrom JP, Labenz J, Stolte M, Dorta G et al. Effect of curing Helicobacter pylori infection on intragastric pH during treatment with omeprazole. Gut 1995;37:743-8.
35. Verdu EF, Armstrong D, Fraser R, Viani F, Idstrom JP, Cederberg C et al. Effect of Helicobacter pylori status on intragastric pH during treatment with omeprazole. Gut 1995;36:539-43.
36. Verdu EF, Armstrong D, Idstrom JP, Labenz J, Stolte M, Borsch G et al. Intragastric pH during treatment with omeprazole: role of Helicobacter pylori and H. pylori-associated gastritis. Scand J Gastroenterol 1996;31:1151-6.
37. Hatlebakk JG, Katz PO, Kuo B, Castell DO. Nocturnal gastric acidity and acid breakthrough on different regimens of omeprazole 40 mg daily. Aliment Pharmacol Ther 1998;12:1235-40.
38. Katz PO, Anderson C, Khoury R, Castell DO. Gastro-oesophageal reflux associated with nocturnal gastric acid breakthrough on proton pump inhibitors. Aliment Pharmacol Ther 1998;12:1231-4.
39. Peghini PL, Katz PO, Castell DO. Ranitidine controls nocturnal gastric acid breakthrough on omeprazole: a controlled study in normal subjects. Gastroenterology 1998;115:1335-9.
40. Raghunath A, Hungin AP, Wooff D, Childs S. Prevalence of Helicobacter pylori in patients with gastro-oesophageal reflux disease: systematic review. BMJ 2003;326:737-42.
41. Newton M, Bryan R, Burnham WR, Kamm MA. Evaluation of Helicobacter pylori in reflux oesophagitis and Barrett's oesophagus. Gut 1997;40:9-13.
42. Pieramico O, Zanetti MV. Relationship between intestinal metaplasia of the gastro-oesophageal junction, Helicobacter pylori infection and gastro-oesophageal reflux disease: a prospective study. Dig Liver Dis 2000;32:567-72.
43. Gisbert JP, de PA, Losa C, Barreiro A, Pajares JM. Helicobacter pylori and gastroesophageal reflux disease: lack of influence of infection on twenty-four-hour esophageal pH monitoring and endoscopic findings. J Clin Gastroenterol 2001;32:210-4.
44. Hackelsberger A, Schultze V, Gunther T, von Arnim U, Manes G, Malfertheiner P. The prevalence of Helicobacter pylori gastritis in patients with reflux oesophagitis: a case-control study. Eur J Gastroenterol Hepatol 1998;10:465-8.
45. Manes G, Mosca S, Laccetti M, Lioniello M, Balzano A. Helicobacter pylori infection, pattern of gastritis, and symptoms in erosive and nonerosive gastroesophageal reflux disease. Scand J Gastroenterol 1999;34:658-62.
46. Liston R, Pitt MA, Banerjee AK. Reflux oesophagitis and Helicobacter pylori infection in elderly patients. Postgrad Med J 1996;72:221-3.
47. Werdmuller BF, Loffeld RJ. Helicobacter pylori infection has no role in the pathogenesis of reflux esophagitis. Dig Dis Sci 1997;42:103-5.
48. Vaezi MF, Falk GW, Peek RM, Vicari JJ, Goldblum JR, Perez-Perez GI et al. CagA-positive strains of Helicobacter pylori may protect against Barrett's esophagus. Am J Gastroenterol 2000;95:2206-11.
49. el-Serag HB, Sonnenberg A, Jamal MM, Inadomi JM, Crooks LA, Feddersen RM. Corpus gastritis is protective against reflux oesophagitis. Gut 1999;45:181-5.
50. Goldblum JR. Inflammation and intestinal metaplasia of the gastric cardia: the role of gastroesophageal reflux and H. pylori infection. Gastroenterology 1998;114:633-9.
51. Varanasi RV, Fantry GT, Wilson KT. Decreased prevalence of Helicobacter pylori infection in gastroesophageal reflux disease. Helicobacter 1998;3:188-94.
52. Vicari JJ. The seroprevalence of cagA-positive Helicobacter pylori strains in the spectrum of gastroesophageal reflux disease. Gastroenterology 1998;115:50-7.
53. Schubert TT, Schnell GA. Prevalence of Campylobacter pylori in patients undergoing upper endoscopy. Am J Gastroenterol 1989;84:637-42.
54. Fallone CA. Determinants of ethnic or geographical differences in infectivity and transmissibility of Helicobacter pylori. Can J Gastroenterol 1999;13:251-5.
55. Shirota T, Kusano M, Kawamura O, Horikoshi T, Mori M, Sekiguchi T. Helicobacter pylori infection correlates with severity of reflux esophagitis: with manometry findings. J Gastroenterol 1999;34:553-9.
56. Wu JC, Sung JJ, Ng EK, Go MY, Chan WB, Chan FK et al. Prevalence and distribution of Helicobacter pylori in gastroesophageal reflux disease: a study from the East. Am J Gastroenterol 1999;94:1790-4.
57. Mihara M, Haruma K, Kamada T, Kiyohira K, Goto T, Sumii M et al. Low prevalence of Helicobacter pylori infection in patients with reflux oesophagitis. Gut 1996;39 Suppl 2:A94.
58. Haruma K, Hamada H, Mihara M, Kamada T, Yoshihara M, Sumii K et al. Negative association between Helicobacter pylori infection and reflux esophagitis in older patients: case-control study in Japan. Helicobacter 2000;5:24-9.
59. Koike T, Ohara S, Sekine H, Iijima K, Abe Y, Kato K et al. Helicobacter pylori infection prevents erosive reflux oesophagitis by decreasing gastric acid secretion. Gut 2001;49:330-4.
60. Graham DY, Yamaoka Y. H. pylori and cagA: relationships with gastric cancer, duodenal ulcer, and reflux esophagitis and its complications. Helicobacter 1998;3:145-51.
61. Lu H, Yamaoka Y, Graham DY. Helicobacter-pylori Virulence factors: facts and fantasies. Curr Opin Gastroenterol 2005;21:653-9.
62. van Herwaarden MA, Samsom M, Smout AJ. Excess gastroesophageal reflux in patients with hiatus hernia is caused by mechanisms other than transient LES relaxations. Gastroenterology 2000;119:1439-46.
63. Hill LD, Kozarek RA. The gastroesophageal flap valve. J Clin Gastroenterol 1999;28:194-7.
64. Mittal RK. Hiatal hernia: myth or reality? Am J Med 1997;103:33S-39S.
65. Mittal RK, Kassab GS. Esophagogastric junction opening: does it explain the difference between normal subjects and patients with reflux disease? Gastroenterology 2003;125:1258-60.
66. Wong WM, Lai KC, Hui WM, Hu WH, Huang JQ, Wong NY et al. Pathophysiology of gastroesophageal reflux diseases in Chinese: role of transient lower esophageal sphincter relaxation and esophageal motor dysfunction. Am J Gastroenterol 2004;99:2088-93.
67. Zerbib F, Bicheler V, Leray V, Joubert M, Bruley des Varannes S, Galmiche JP. H. pylori and transient lower esophageal sphincter relaxations induced by gastric distension in healthy humans. Am J Physiol Gastrointest Liver Physiol 2001;281:G350-G356.
68. Tanaka I, Tatsumi Y, Kodama T, Kato K, Fujita S, Mitsufuji S et al. Effect of Helicobacter pylori eradication on gastroesophageal function. J Gastroenterol Hepatol 2004;19:251-7.
69. Tsai SH, Chen CM, Chang CS, Chen GH. Effect of Helicobacter pylori infection on intragastric acidity in patients with reflux esophagitis. J Gastroenterol 2004;39:821-6.
70. Graham DY, Opekun AR, Yamaoka Y, Osato MS, El Zimaity HM. Early events in proton pump inhibitor-associated exacerbation of corpus gastritis. Aliment Pharmacol Ther 2003;17:193-200.
71. Graham DY. Campylobacter pylori and peptic ulcer disease. Gastroenterology 1989;96:615-25.
72. Unge P, Gad A, Gnarpe H, Olsson J. Does omeprazole improve antimicrobial therapy directed towards gastric Campylobacter pylori in patients with antral gastritis? A pilot study. Scand J Gastroenterol Suppl 1989;167:49-54.
73. Kuipers EJ, Uyterlinde AM, Pena AS, Hazenberg HJ, Bloemena E, Lindeman J et al. Increase of Helicobacter pylori-associated corpus gastritis during acid suppressive therapy: implications for long-term safety. Am J Gastroenterol 1995;90:1401-6.
74. Kuipers EJ, Lundell L, Klinkenberg-Knol EC, Havu N, Festen HP, Liedman B et al. Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N Engl J Med 1996;334:1018-22.
75. Hunt R, Fallone C, Veldhuyzan van ZS, Sherman P, Smaill F, Flook N et al. Canadian Helicobacter Study Group Consensus Conference: update on the management of Helicobacter pylori: an evidence-based evaluation of six topics relevant to clinical outcomes in patients evaluated for H pylori infection. Can J Gastroenterol 2004;18:547-54.
76. Malfertheiner P, Megraud F, O'Morain C, Hungin AP, Jones R, Axon A et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 2002;16:167-80.
77. Friedel DM, Gbadehan E. Rebound hypersecretion after omeprazole. Gastroenterology 1999;117:513-4.
78. Kuipers EJ, Klinkenberg-Knol EC. Helicobacter pylori, acid, and omeprazole revisited: bacterial eradication and rebound hypersecretion. Gastroenterology 1999;116:479-83.
79. McColl KE, El Omar E, Gillen D. Helicobacter pylori gastritis and gastric physiology. Gastroenterol Clin North Am 2000;29:687-703, viii.
80. Ford A, Moayyedi P. How can the current strategies for Helicobacter pylori eradication therapy be improved? Can J Gastroenterol 2003;17 Suppl B:36B-40B.
81. Graham DY. Can therapy ever be denied for Helicobacter pylori infection? Gastroenterology 1997;113:6 Suppl):S113-7.
82. Shiotani A, Nurgalieva ZZ, Yamaoka Y, Graham DY. Helicobacter pylori. Med Clin North Am 2000;84:1125-36.
83. Zullo A, Vaira D, Vakil N, Hassan C, Gatta L, Ricci C et al. High eradication rates of Helicobacter pylori with a new sequential treatment. Aliment Pharmacol Ther 2003;17:719-26.
84. De Francesco V, Zullo A, Hassan C, Della VN, Pietrini L, Minenna MF et al. The prolongation of triple therapy for Helicobacter pylori does not allow reaching therapeutic outcome of sequential scheme: a prospective, randomised study. Dig Liver Dis 2004;36:322-6.
85. Francavilla R, Lionetti E, Castellaneta SP, Magista AM, Boscarelli G, Piscitelli D et al. Improved efficacy of 10-Day sequential treatment for Helicobacter pylori eradication in children: a randomized trial. Gastroenterology 2005;129:1414-9.
86. Zullo A, Gatta L, De Francesco V, Hassan C, Ricci C, Bernabucci V et al. High rate of Helicobacter pylori eradication with sequential therapy in elderly patients with peptic ulcer: a prospective controlled study. Aliment Pharmacol Ther 2005;21:1419-24.
87. Saad RJ, Schoenfeld P, Kim HM, Chey WD. Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis. Am J Gastroenterol 2006;101:488-96.
88. Branca G, Spanu T, Cammarota G, Schito AM, Gasbarrini A, Gasbarrini GB et al. High levels of dual resistance to clarithromycin and metronidazole and in vitro activity of levofloxacin against Helicobacter pylori isolates from patients after failure of therapy. Int J Antimicrob Agents 2004;24:433-8.
89. Kim JM, Kim JS, Kim N, Jung HC, Song IS. Distribution of fluoroquinolone MICs in Helicobacter pylori strains from Korean patients. J Antimicrob Chemother 2005;56:965-7.
90. Cabrita J, Oleastro M, Matos R, Manhente A, Cabral J, Barros R et al. Features and trends in Helicobacter pylori antibiotic resistance in Lisbon area, Portugal (1990-1999) J Antimicrob Chemother 2000;46:1029-31.
91. Nagahara A, Miwa H, Ogawa K, Kurosawa A, Ohkura R, Iida N et al. Addition of metronidazole to rabeprazole-amoxicillin-clarithromycin regimen for Helicobacter pylori infection provides an excellent cure rate with five-day therapy. Helicobacter 2000;5:88-93.
92. Treiber G, Ammon S, Schneider E, Klotz U. Amoxicillin/metronidazole/ omeprazole/clarithromycin: a new, short quadruple therapy for Helicobacter pylori eradication. Helicobacter 1998;3:54-8.
93. Gisbert JP, Pajares JM. Helicobacter pylori "rescue" therapy after failure of two eradication treatments. Helicobacter 2005;10:363-72.
94. Graham DY, Osato MS, Hoffman J, Opekun AR, Anderson S, El-Zimaity HM. Furazolidone combination therapies for Helicobacter pylori infection in the United States. Aliment Pharmacol Ther 2000;14:211-5.
95. Bayerdorffer E, Miehlke S, Mannes GA, Sommer A, Hochter W, Weingart J et al. Double-blind trial of omeprazole and amoxicillin to cure Helicobacter pylori infection in patients with duodenal ulcers. Gastroenterology 1995;108:1412-7.
96. Miehlke S, Mannes GA, Lehn N, Hele C, Stolte M, Bayerdorffer E. An increasing dose of omeprazole combined with amoxicillin cures Helicobacter pylori infection more effectively. Aliment Pharmacol Ther 1997;11:323-9.
97. Miehlke S, Kirsch C, Schneider-Brachert W, Haferland C, Neumeyer M, Bastlein E et al. A prospective, randomized study of quadruple therapy and high-dose dual therapy for treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin. Helicobacter 2003;8:310-9.
98. Graham DY, Abudayyeh S, El-Zimaity HM, Hoffman J, Reddy R, Opekun AR. Sequential therapy using high-dose esomeprazole-amoxicllin followed by gatifloxacin for H. pylori infection. Aliment Pharmacol Therap 2006;24:845-50.
99. Rodriguez-Torres M, Salgado-Mercado R, Rios-Bedoya CF, Ponte-Rivera E, Marxuach-Cuetara AM, Rodriguez-Orengo JF et al. High eradication rates of Helicobacter pylori infection with first- and second-line combination of esomeprazole, tetracycline, and metronidazole in patients allergic to penicillin. Dig Dis Sci 2005;50:634-9.